Interaction of an Alkylating Camptothecin Derivative with a DNA Base at Topoisomerase I-DNA Cleavage Sites

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1995 Sep 12

PMID 7568032

Citations 23

Authors

Y Pommier

G Kohlhagen

K W Kohn

F Leteurtre

M C Wani

M E Wall

Affiliations

Soon will be listed here.

Abstract

DNA topoisomerase I (top1) is a ubiquitous nuclear enzyme. It is specifically inhibited by camptothecin, a natural product derived from the bark of the tree Camptotheca acuminata. Camptothecin and several of its derivatives are presently in clinical trial and exhibit remarkable anticancer activity. The present study is a further investigation of the molecular interactions between the drug and the enzyme-DNA complex. We utilized an alkylating camptothecin derivative, 7-chloromethyl-10,11-methylenedioxycamptothecin (7-ClMe-MDO-CPT), and compared its activity against calf thymus top1 in a DNA oligonucleotide containing a single top1 cleavage site with the activity of its nonalkylating analog, 7-ethyl-10,11-methylenedioxycamptothecin (7-Et-MDO-CPT). In the presence of top1, 7-ClMe-MDO-CPT produced a DNA fragment that migrated more slowly than the top1-cleaved DNA fragment observed with 7-Et-MDO-CPT. Top1 was unable to religate this fragment in the presence of high NaCl concentration or proteinase K at 50 degrees C. This fragment was resistant to piperidine treatment and was also formed with an oligonucleotide containing a 7-deazaguanine at the 5' terminus of the top1-cleaved DNA (base + 1). It was however cleaved by formic acid treatment followed by piperidine. These observations are consistent with alkylation of the +1 base (adenine or guanine) by 7-ClMe-MDO-CPT in the presence of top1 covalent complexes and provide direct evidence that camptothecins inhibit top1 by binding at the enzyme-DNA interface.

Citing Articles

Novel Camptothecin Derivative 9c with Enhanced Antitumor Activity via NSA2-EGFR-P53 Signaling Pathway.

Du F, Zhang A, Qi X, Yin R, Jiang T, Li J Int J Mol Sci. 2025; 26(5).

PMID: 40076615 PMC: 11900506. DOI: 10.3390/ijms26051987.

DNA Damage Response Mutants Challenged with Genotoxic Agents-A Different Experimental Approach to Investigate the and Genes.

Bertoncini A, Pagano P, Macovei A Genes (Basel). 2025; 16(1).

PMID: 39858650 PMC: 11765484. DOI: 10.3390/genes16010103.

Two-ended recombination at a Flp-nickase-broken replication fork.

Elango R, Nilavar N, Li A, Nguyen D, Rass E, Duffey E Mol Cell. 2024; 85(1):78-90.e3.

PMID: 39631396 PMC: 11733529. DOI: 10.1016/j.molcel.2024.11.006.

One-ended and two-ended breaks at nickase-broken replication forks.

Scully R, Walter J, Nussenzweig A DNA Repair (Amst). 2024; 144:103783.

PMID: 39504607 PMC: 11681922. DOI: 10.1016/j.dnarep.2024.103783.

Molecular Docking and Dynamics Simulation Revealed the Potential Inhibitory Activity of New Drugs against Human Topoisomerase I Receptor.

Madeddu F, Martino J, Pieroni M, Del Buono D, Bottoni P, Botta L Int J Mol Sci. 2022; 23(23).

PMID: 36498979 PMC: 9737192. DOI: 10.3390/ijms232314652.

References

Capranico G, Kohn K, Pommier Y . Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res. 1990; 18(22):6611-9. PMC: 332618. DOI: 10.1093/nar/18.22.6611. View

Wang J . DNA topoisomerases: why so many?. J Biol Chem. 1991; 266(11):6659-62. View

Fosse P, Rene B, Le Bret M, Paoletti C, Saucier J . Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative. Nucleic Acids Res. 1991; 19(11):2861-8. PMC: 328243. DOI: 10.1093/nar/19.11.2861. View

Jaxel C, Capranico G, Kerrigan D, Kohn K, Pommier Y . Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem. 1991; 266(30):20418-23. View

Pommier Y, Capranico G, Orr A, Kohn K . Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. Nucleic Acids Res. 1991; 19(21):5973-80. PMC: 329055. DOI: 10.1093/nar/19.21.5973. View

Svejstrup J, Christiansen K, GROMOVA I, Andersen A, Westergaard O . New technique for uncoupling the cleavage and religation reactions of eukaryotic topoisomerase I. The mode of action of camptothecin at a specific recognition site. J Mol Biol. 1991; 222(3):669-78. DOI: 10.1016/0022-2836(91)90503-x. View

Sawada S, Nokata K, Furuta T, Yokokura T, Miyasaka T . Chemical modification of an antitumor alkaloid camptothecin: synthesis and antitumor activity of 7-C-substituted camptothecins. Chem Pharm Bull (Tokyo). 1991; 39(10):2574-80. DOI: 10.1248/cpb.39.2574. View

Crow R, Crothers D . Structural modifications of camptothecin and effects on topoisomerase I inhibition. J Med Chem. 1992; 35(22):4160-4. DOI: 10.1021/jm00100a022. View

Slichenmyer W, Rowinsky E, Donehower R, Kaufmann S . The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst. 1993; 85(4):271-91. DOI: 10.1093/jnci/85.4.271. View

10.

Leteurtre F, Fesen M, Kohlhagen G, Kohn K, Pommier Y . Specific interaction of camptothecin, a topoisomerase I inhibitor, with guanine residues of DNA detected by photoactivation at 365 nm. Biochemistry. 1993; 32(34):8955-62. DOI: 10.1021/bi00085a029. View

11.

Tanizawa A, Beitrand R, Kohlhagen G, Tabuchi A, Jenkins J, Pommier Y . Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. J Biol Chem. 1993; 268(34):25463-8. View

12.

Tanizawa A, Kohn K, Pommier Y . Induction of cleavage in topoisomerase I c-DNA by topoisomerase I enzymes from calf thymus and wheat germ in the presence and absence of camptothecin. Nucleic Acids Res. 1993; 21(22):5157-66. PMC: 310631. DOI: 10.1093/nar/21.22.5157. View

13.

Capranico G, Palumbo M, Tinelli S, Mabilia M, POZZAN A, Zunino F . Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage. J Mol Biol. 1994; 235(4):1218-30. DOI: 10.1006/jmbi.1994.1075. View

14.

POTMESIL M . Camptothecins: from bench research to hospital wards. Cancer Res. 1994; 54(6):1431-9. View

15.

Tanizawa A, Fujimori A, Fujimori Y, Pommier Y . Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst. 1994; 86(11):836-42. DOI: 10.1093/jnci/86.11.836. View

16.

Chen A, Liu L . DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol. 1994; 34:191-218. DOI: 10.1146/annurev.pa.34.040194.001203. View

17.

Pommier Y, Leteurtre F, Fesen M, Fujimori A, Bertrand R, Solary E . Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 1994; 12(5):530-42. DOI: 10.3109/07357909409021413. View

18.

Leteurtre F, Fujimori A, Tanizawa A, Chhabra A, Mazumder A, Kohlhagen G . Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions. J Biol Chem. 1994; 269(46):28702-7. View

19.

Freudenreich C, Kreuzer K . Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex. Proc Natl Acad Sci U S A. 1994; 91(23):11007-11. PMC: 45155. DOI: 10.1073/pnas.91.23.11007. View

20.

Luzzio M, Besterman J, Emerson D, Evans M, Lackey K, Leitner P . Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. J Med Chem. 1995; 38(3):395-401. DOI: 10.1021/jm00003a001. View